Effect of octreotide in the prevention of doxorubicin cardiotoxicity.
OBJECTIVE
A precise method for prevention from doxorubicin cardiotoxicity is not known. We examined whether octreotide has a protective effect against doxorubicin cardiotoxicity.


METHODS
New Zealand rabbits (n=44) were divided into 4 groups according to drugs given: Group A (n=12) doxorubicin and octreotide, Group B (n=12) only doxorubicin, Group C (n=10) only octreotide and Group D (n=10) only saline. Effects of the drugs were evaluated in terms of histopathological score, fractional shortening (FS) and prolongation of the QTc interval.


RESULTS
Mean pathological score for cardiotoxicity (Group A: 3.7+/-0.5, Group B: 3.9+/-0.3), prolongation of QTc (Group A: from 244.5+/-21.2 ms to 282.9+/-25.9 ms, p<0.0001; Group B: from 248.5+/-17.7 ms to 298.3+/-13.7 ms, p<0.00001) and the rate of decrease in FS (Group A: from 34.4+/-2.0 to 28.0+/-2.0, p<0.05; Group B: from 35.1+/-1.9 to 24.8+/-1.3, p<0.05) were higher in Group B when compared to Group A, but only difference in the rate of decrease in FS was statistically significant (p<0.001). None of these variables changed significantly in groups C and D.


CONCLUSIONS
In this preliminary study, octreotide seems not to reduce doxorubicin cardiotoxicity. On the other hand, a consistent tendency of decreased cardiotoxicity in octreotide+doxorubicin group was observed, although only the difference in FS decrease was significant. Further investigations are needed to address the issue of the extent and the mechanisms of this effect.
Barçin
Cem
C
Department of Cardiology, Gulhane Military Medical Academy, Ankara, Turkey. cembarcin@yahoo.com
Kurşaklioğlu
Hürkan
H
Safali
Mükerrem
M
Iyisoy
Atilla
A
Köse
Sedat Bengi
SB
Barindik
Nadir
N
Işik
Ersoy
E
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D004317:Doxorubicin / Q000633:toxicity*; D004452:Echocardiography; D006321:Heart / Q000187:drug effects*; D006329:Heart Conduction System / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D015282:Octreotide / Q000008:administration & dosage*; D011817:Rabbits
D000903:Antibiotics, Antineoplastic; D002316:Cardiotonic Agents; D004317:Doxorubicin; D015282:Octreotide